CCM
MRSN

Coldstream Capital Management’s Mersana Therapeutics MRSN Stock Holding History

Coldstream Capital Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-44
Closed -$377 – 2460
2025
Q1 		$377 Buy
+44
New +$679 ﹤0.01% 3410

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Coldstream Capital Management's MRSN Position: Q2 2025 in Review

Coldstream Capital Management sold out of Mersana Therapeutics (MRSN) in Q2 2025, closing a stake of 44 shares — an estimated $377 sold.

Coldstream Capital Management first reported a position in MRSN in Q1 2025 and held it in 1 quarter. The position peaked at $377 in Q1 2025. 83 funds tracked by Wall St. Rank hold MRSN as of Q2 2025.

  • Coldstream Capital Management reported no remaining Mersana Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 44 Mersana Therapeutics shares in Q2 2025, an estimated $377.
  • Coldstream Capital Management first reported a position in Mersana Therapeutics in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Mersana Therapeutics position peaked at $377 in Q1 2025.
  • 83 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.